Jazz Pharmaceuticals (JAZZ) Change in Accured Expenses (2010 - 2026)

Jazz Pharmaceuticals' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$7.9 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 372.41% year-over-year to -$7.9 million; the TTM figure through Mar 2026 stood at $17.2 million (down 68.34% YoY), while the FY2025 annual figure was $28.0 million, down 67.48% from the prior year.
• Change in Accured Expenses was -$7.9 million for Q1 2026 at Jazz Pharmaceuticals, up from -$22.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $148.1 million in Q4 2022 to a low of -$97.0 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged $14.6 million across 5 years, with a median of $7.2 million in 2023.
• Biggest YoY gain for Change in Accured Expenses was 276.64% in 2024; the steepest drop was 507.87% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $148.1 million in 2022, then tumbled by 64.45% to $52.7 million in 2023, then tumbled by 43.54% to $29.7 million in 2024, then plunged by 177.05% to -$22.9 million in 2025, then soared by 65.51% to -$7.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$7.9 million (Q1 2026), -$22.9 million (Q4 2025), and $126.3 million (Q3 2025), per Business Quant data.